Hyunbum Jang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hyunbum Jang has a total of 111 co-authors. Here are the top co-authors by number of shared publications:
- Ruth Nussinov
Frederick National Laboratory for Cancer Research
74 shared publications - Mingzhen Zhang
Frederick National Laboratory for Cancer Research, Frederick, MD
12 shared publications Yonglan Liu
Cancer Innovation Laboratory
12 shared publicationsMingzhen Zhang
Computational Structural Biology Section, Frederick National Laboratory for Cancer Research, Frederick, USA
9 shared publications- Bengi Ruken Yavuz
National Cancer Institute
7 shared publications - Vadim Gaponenko
Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, IL 60607, USA
7 shared publications
Latest Publications
- Open Access
- 22 October 2026
- Published by AIP Publishing in The Journal of Chemical Physics
- Vol. 165 (16)
Allostery in the Ras-Raf-PI3K-PTEN signaling network at the membrane: Implications for drug discovery
Here, we review the active roles and mechanisms of the plasma membrane and phospholipids in peripheral membrane proteins and lipid-anchored membrane proteins, focusing on the Ras-Raf-PI3K-PTEN signaling network. Data for some phospholipids are scant (or non-existent), whereas for others the mechanistic details are often incomplete—likely due to the challenging nature of membrane dynamics. Identification of the direct, specific interactions of the phospholipids with proteins is often lacking; instead, these lipids are frequently described as creating a negatively charged lipid environment, transiently interacting with proteins. To clarify these elusive yet cardinal mechanisms, we contrast lipid-coupled conformational changes with macroscopic bilayer effects—including altered dimensionality, curvature, and lateral pressure—that collectively modulate protein function by shifting conformational ensembles and local concentration. These lead us to consider specific lipid-binding allostery, membrane-property-mediated conformational coupling, recruitment and orientation effects, and proximity, avidity, and clustering effects. While specific lipid–protein interactions are often transient, both components serve vital active roles in protein function. This is reinforced by distinguishing between canonical, site-specific allosteric regulation and broader membrane-mediated phenomena. Pharmacology at the membrane has been challenging; direct specific lipid-binding allostery is complicated by the often-transient membrane lipid–protein interactions. Coupled with macroscopic bilayer effects, such pharmacology can elicit toxic side-effects. Specifically targeting the regulation of membrane-associated proteins, autoinhibition and activation, may fare better in the clinic. The Ras-Raf-PI3K-PTEN signaling network, which is anchored and controlled by membrane interaction and can be viewed as the heart of cell proliferation, is an especially relevant system to explore.
- 22 October 2026
- Published by AIP Publishing in The Journal of Chemical Physics
- Vol. 165 (16)
Open AccessAllostery in the Ras-Raf-PI3K-PTEN signaling network at the membrane: Implications for drug discovery
Here, we review the active roles and mechanisms of the plasma membrane and phospholipids in peripheral membrane proteins and lipid-anchored membrane proteins, focusing on the Ras-Raf-PI3K-PTEN signaling network. Data for some phospholipids are scant (or non-existent), whereas for others the mechanistic details are often incomplete—likely due to the challenging nature of membrane dynamics. Identification of the direct, specific interactions of the phospholipids with proteins is often lacking; instead, these lipids are frequently described as creating a negatively charged lipid environment, transiently interacting with proteins. To clarify these elusive yet cardinal mechanisms, we contrast lipid-coupled conformational changes with macroscopic bilayer effects—including altered dimensionality, curvature, and lateral pressure—that collectively modulate protein function by shifting conformational ensembles and local concentration. These lead us to consider specific lipid-binding allostery, membrane-property-mediated conformational coupling, recruitment and orientation effects, and proximity, avidity, and clustering effects. While specific lipid–protein interactions are often transient, both components serve vital active roles in protein function. This is reinforced by distinguishing between canonical, site-specific allosteric regulation and broader membrane-mediated phenomena. Pharmacology at the membrane has been challenging; direct specific lipid-binding allostery is complicated by the often-transient membrane lipid–protein interactions. Coupled with macroscopic bilayer effects, such pharmacology can elicit toxic side-effects. Specifically targeting the regulation of membrane-associated proteins, autoinhibition and activation, may fare better in the clinic. The Ras-Raf-PI3K-PTEN signaling network, which is anchored and controlled by membrane interaction and can be viewed as the heart of cell proliferation, is an especially relevant system to explore.
- Open Access
- 8 October 2026
- Published by Royal Society of Chemistry (RSC) in RSC Chemical Biology
- Vol. 7 (10) , 1958-1971
Kinase cascades: emerging design principles and guidelines
Activation energy barriers indicate that the Raf–MEK–ERK pathway operates via a sequential kinase cascade. Conversely, the PI3K, PDK, AKT, and mTOR pathway relies on lipid second messengers and multiple phosphorylation steps.
- 8 October 2026
- Published by Royal Society of Chemistry (RSC) in RSC Chemical Biology
- Vol. 7 (10) , 1958-1971
Open AccessKinase cascades: emerging design principles and guidelines
Activation energy barriers indicate that the Raf–MEK–ERK pathway operates via a sequential kinase cascade. Conversely, the PI3K, PDK, AKT, and mTOR pathway relies on lipid second messengers and multiple phosphorylation steps.
- Open Access
- 29 September 2026
- Published by Elsevier in Current Opinion in Structural Biology
- Vol. 101
From static structures to dynamic energy landscapes: the latest revolution in molecular biology
- 29 September 2026
- Published by Elsevier in Current Opinion in Structural Biology
- Vol. 101
Open AccessFrom static structures to dynamic energy landscapes: the latest revolution in molecular biology
- Open Access
- 7 September 2026
- Published by Wiley in Medicinal Research Reviews
Molecular Glue Degraders in Early Development for Cancer Therapy
Molecular glue degraders are an emerging class of small molecule allosteric modulators that induce or stabilize protein‐protein interactions, enabling targeted degradation of previously intractable proteins. By redirecting E3 ligases to recognize neosubstrates, proteins that are not typically recognized by a specific E3 ubiquitin ligase, they expand the scope of drug discovery beyond traditional paradigms. We review mechanistic principles underlying molecular glue activity, including cooperativity, weak affinity interactions, structural degrons, and higher‐order complex formation. We discuss discovery strategies, from serendipitous identification to emerging rational and chemoproteomic approaches, and key E3 ligase systems with relevance to oncology. We highlight clinical and preclinical applications, alongside challenges such as resistance mechanisms, context‐dependent activity, and limitations in predicting neosubstrates. Molecular glues are transitioning from serendipitous discoveries to a mechanism‐driven therapeutic platform. Progress depends on integrating structural biology, proteomics, and computational modeling to enable rational design and improve predictability. Expanding the repertoire of E3 ligases and understanding context‐specific degradation will be critical to fully realize their potential in oncology and beyond.
- 7 September 2026
- Published by Wiley in Medicinal Research Reviews
Open AccessMolecular Glue Degraders in Early Development for Cancer Therapy
Molecular glue degraders are an emerging class of small molecule allosteric modulators that induce or stabilize protein‐protein interactions, enabling targeted degradation of previously intractable proteins. By redirecting E3 ligases to recognize neosubstrates, proteins that are not typically recognized by a specific E3 ubiquitin ligase, they expand the scope of drug discovery beyond traditional paradigms. We review mechanistic principles underlying molecular glue activity, including cooperativity, weak affinity interactions, structural degrons, and higher‐order complex formation. We discuss discovery strategies, from serendipitous identification to emerging rational and chemoproteomic approaches, and key E3 ligase systems with relevance to oncology. We highlight clinical and preclinical applications, alongside challenges such as resistance mechanisms, context‐dependent activity, and limitations in predicting neosubstrates. Molecular glues are transitioning from serendipitous discoveries to a mechanism‐driven therapeutic platform. Progress depends on integrating structural biology, proteomics, and computational modeling to enable rational design and improve predictability. Expanding the repertoire of E3 ligases and understanding context‐specific degradation will be critical to fully realize their potential in oncology and beyond.
- Open Access
Single-Cell Mapping of Malignant Signaling Networks Guides Drug Combinations
Single-cell breast cancer atlases reveal malignant, immune, and stromal diversity; however, how the recurrent signaling pathways drive untreated malignant-cell states and could inform combination therapy remains unclear. Here, we analyzed 15,753 malignant cells from untreated primary breast tumors using a cell-resolved network framework. Individual transcriptomes were projected onto a protein-protein interaction network, partitioned into Leiden communities, and annotated by pathway enrichment. Pathway recurrence was evaluated against matched null models preserving community size, protein-network degree, and gene detection rate. Before null correction, recurrent pathways included PI3K/AKT, MAPK, JAK/STAT, and HIF-1 (hypoxia-inducible factor 1) signaling. After correction, HIF-1 emerged as the dominant recurrent signal across patients, indicating convergence of diverse upstream pathways on a shared hypoxia- and stress-adaptive malignant-cell program. The recurrent JAK/STAT, cAMP, glucagon, oxytocin, and thyroid hormone signaling suggest inflammatory, metabolic, and endocrine crosstalk. These findings support rational drug combinations targeting HIF-1 together with upstream PI3K/AKT/mTOR, MAPK, or JAK/STAT signaling.
Open AccessSingle-Cell Mapping of Malignant Signaling Networks Guides Drug Combinations
Single-cell breast cancer atlases reveal malignant, immune, and stromal diversity; however, how the recurrent signaling pathways drive untreated malignant-cell states and could inform combination therapy remains unclear. Here, we analyzed 15,753 malignant cells from untreated primary breast tumors using a cell-resolved network framework. Individual transcriptomes were projected onto a protein-protein interaction network, partitioned into Leiden communities, and annotated by pathway enrichment. Pathway recurrence was evaluated against matched null models preserving community size, protein-network degree, and gene detection rate. Before null correction, recurrent pathways included PI3K/AKT, MAPK, JAK/STAT, and HIF-1 (hypoxia-inducible factor 1) signaling. After correction, HIF-1 emerged as the dominant recurrent signal across patients, indicating convergence of diverse upstream pathways on a shared hypoxia- and stress-adaptive malignant-cell program. The recurrent JAK/STAT, cAMP, glucagon, oxytocin, and thyroid hormone signaling suggest inflammatory, metabolic, and endocrine crosstalk. These findings support rational drug combinations targeting HIF-1 together with upstream PI3K/AKT/mTOR, MAPK, or JAK/STAT signaling.
- Open Access
- 30 July 2026
- Published by American Chemical Society (ACS) in The Journal of Physical Chemistry B
- Vol. 130 (32) , 8174-8185
How Functional Variants Reconfigure the Rac2 Conformational Landscape
Rac2, a member of the Rho family of small GTPases, is a fundamental regulator of essential cellular processes. Pathogenic substitutions near and within the Switch II region, specifically D57N and E62K, have been implicated in oncogenesis and immunodeficiency. Despite their proximity, D57N is characterized as a loss-of-function mutation, while E62K is a constitutively active, gain-of-function mutation. In this study, we addressed several critical questions: (i) the structural basis of their altered cellular functions, (ii) how these variants rearrange the conformational ensemble, and (iii) the subsequent impact on cellular signaling networks. Using molecular dynamics (MD) simulations, we characterized the conformational dynamics of these Rac2 variants in GDP- and GTP-bound states. Our results demonstrate that Rac2D57N predominantly adopts an inactive-like conformation, regardless of the bound nucleotide. GTP binding is insufficient to induce the canonical active state in this mutant. Conversely, Rac2E62K maintains a nucleotide-dependent toggle, appearing inactive when bound to GDP and active when bound to GTP. Additionally, we examined the assembly of these variants with the regulator p50-RhoGAP. In the wild-type complex, GAP binding facilitates a shift toward a near-transition-state ensemble. In stark contrast, both the D57N and E62K complexes remain sequestered in a ground-ON state configuration, effectively trapping the GTPase and hindering GAP-mediated hydrolysis. While both Rac2 mutations result in immune system dysfunction, the underlying mechanisms are opposite: inactive vs overactive. This work provides a high-resolution, mechanistic framework for understanding how localized perturbations in the switch loops landscape dictate systemic cellular outcomes.
- 30 July 2026
- Published by American Chemical Society (ACS) in The Journal of Physical Chemistry B
- Vol. 130 (32) , 8174-8185
Open AccessHow Functional Variants Reconfigure the Rac2 Conformational Landscape
Rac2, a member of the Rho family of small GTPases, is a fundamental regulator of essential cellular processes. Pathogenic substitutions near and within the Switch II region, specifically D57N and E62K, have been implicated in oncogenesis and immunodeficiency. Despite their proximity, D57N is characterized as a loss-of-function mutation, while E62K is a constitutively active, gain-of-function mutation. In this study, we addressed several critical questions: (i) the structural basis of their altered cellular functions, (ii) how these variants rearrange the conformational ensemble, and (iii) the subsequent impact on cellular signaling networks. Using molecular dynamics (MD) simulations, we characterized the conformational dynamics of these Rac2 variants in GDP- and GTP-bound states. Our results demonstrate that Rac2D57N predominantly adopts an inactive-like conformation, regardless of the bound nucleotide. GTP binding is insufficient to induce the canonical active state in this mutant. Conversely, Rac2E62K maintains a nucleotide-dependent toggle, appearing inactive when bound to GDP and active when bound to GTP. Additionally, we examined the assembly of these variants with the regulator p50-RhoGAP. In the wild-type complex, GAP binding facilitates a shift toward a near-transition-state ensemble. In stark contrast, both the D57N and E62K complexes remain sequestered in a ground-ON state configuration, effectively trapping the GTPase and hindering GAP-mediated hydrolysis. While both Rac2 mutations result in immune system dysfunction, the underlying mechanisms are opposite: inactive vs overactive. This work provides a high-resolution, mechanistic framework for understanding how localized perturbations in the switch loops landscape dictate systemic cellular outcomes.
- Open Access
- 11 June 2026
- Published by Elsevier in Current Opinion in Structural Biology
- Vol. 99, 103302
Spatial biology of crowded tumor cells: A new map for designing drug combinations
- 11 June 2026
- Published by Elsevier in Current Opinion in Structural Biology
- Vol. 99, 103302
Open AccessSpatial biology of crowded tumor cells: A new map for designing drug combinations
- Open Access
- 27 May 2026
- Published by Wiley in Protein Science
- Vol. 35 (6) , e70650
ERK autoinhibition mechanism informs a drug combination strategy
ERK is a key regulator in the MAPK pathway, controlling essential cell processes through dual‐phosphorylation‐based activation. We investigate the conformational equilibrium between inactive and active ERK states, which is controlled allosterically by its structurally unique C‐terminal L16 segment. Using molecular dynamics simulations of full‐length and truncated ERK variants across phosphorylation states, we demonstrate that activation is achieved through a lateral αC‐helix rotation initiated by dual‐phosphorylation. The L16 segment intrinsically stabilizes the inactive kinase conformation by restricting αC‐helix orientation, counteracting its natural tendency to adopt an active alignment. Removal of the L16 loop disrupts the unphosphorylated state, whereas all phosphorylated systems remain stable. The α L 16‐helix restricts the movements of αC‐helix, ensuring controlled conformational transitions. Disruption of L16 segment's constraints through modification or cellular processes lowers the activation barrier, rendering kinase activation under partial phosphorylation. Importantly, we discovered an L16 segment‐associated cryptic pocket, whose (allosteric) targeting in combination with orthosteric inhibitors that selectively bind the active state, appears a promising therapeutic strategy. Currently, no direct ERK allosteric and orthosteric drug combination is available. This discovery has been potentiated by a mechanistic understanding of ERK autoinhibition which informs L16's potential as a cryptic binding site for ERK dysregulation.
- 27 May 2026
- Published by Wiley in Protein Science
- Vol. 35 (6) , e70650
Open AccessERK autoinhibition mechanism informs a drug combination strategy
ERK is a key regulator in the MAPK pathway, controlling essential cell processes through dual‐phosphorylation‐based activation. We investigate the conformational equilibrium between inactive and active ERK states, which is controlled allosterically by its structurally unique C‐terminal L16 segment. Using molecular dynamics simulations of full‐length and truncated ERK variants across phosphorylation states, we demonstrate that activation is achieved through a lateral αC‐helix rotation initiated by dual‐phosphorylation. The L16 segment intrinsically stabilizes the inactive kinase conformation by restricting αC‐helix orientation, counteracting its natural tendency to adopt an active alignment. Removal of the L16 loop disrupts the unphosphorylated state, whereas all phosphorylated systems remain stable. The α L 16‐helix restricts the movements of αC‐helix, ensuring controlled conformational transitions. Disruption of L16 segment's constraints through modification or cellular processes lowers the activation barrier, rendering kinase activation under partial phosphorylation. Importantly, we discovered an L16 segment‐associated cryptic pocket, whose (allosteric) targeting in combination with orthosteric inhibitors that selectively bind the active state, appears a promising therapeutic strategy. Currently, no direct ERK allosteric and orthosteric drug combination is available. This discovery has been potentiated by a mechanistic understanding of ERK autoinhibition which informs L16's potential as a cryptic binding site for ERK dysregulation.
- Open Access
The structural basis of RanGAP1 regulation and catalysis in nuclear transport
RanGAP1 promotes GTP hydrolysis of nuclear pore complex (NPC) transport complexes at the cytoplasmic face. A disordered linker connects its catalytic GAP domain to the C-terminal sumoylation domain, anchoring into NPC’s cytoplasmic filaments. This arrangement raises the question of how these distinct functions are coordinated within a crowded cellular environment. Using atomistic molecular dynamics simulations, we show that RanGAP1 adopts an autoinhibited conformation, where the C-terminal domain masks the catalytic GAP domain. Sumoylation allosterically relieves this autoinhibition, enabling GTP-bound Ran access to the GAP domain. In the cytosol, Ran-GTP/RanBP1 can bind a less populated open conformation of RanGAP1, providing a backup mechanism for GTP hydrolysis in Ran. Importantly, we observe that Arg191 of human RanGAP1 inserts into the GTP-binding pocket of Ran and directly interacts with the γ-phosphate, consistent with a canonical arginine finger. This observation contrasts with earlier models derived from yeast RanGAP and suggests that human RanGAP1 may follow a catalytic mechanism similar to classical small GTPase regulators like NF1. Together, these findings provide a framework of RanGAP1, linking autoinhibition, sumoylation, spatial organization at the NPC, and the catalytic mechanism. They also highlight how conformational regulation and post-translational modification coordinate efficient GTP hydrolysis in Ran during nuclear transport.
Open AccessThe structural basis of RanGAP1 regulation and catalysis in nuclear transport
RanGAP1 promotes GTP hydrolysis of nuclear pore complex (NPC) transport complexes at the cytoplasmic face. A disordered linker connects its catalytic GAP domain to the C-terminal sumoylation domain, anchoring into NPC’s cytoplasmic filaments. This arrangement raises the question of how these distinct functions are coordinated within a crowded cellular environment. Using atomistic molecular dynamics simulations, we show that RanGAP1 adopts an autoinhibited conformation, where the C-terminal domain masks the catalytic GAP domain. Sumoylation allosterically relieves this autoinhibition, enabling GTP-bound Ran access to the GAP domain. In the cytosol, Ran-GTP/RanBP1 can bind a less populated open conformation of RanGAP1, providing a backup mechanism for GTP hydrolysis in Ran. Importantly, we observe that Arg191 of human RanGAP1 inserts into the GTP-binding pocket of Ran and directly interacts with the γ-phosphate, consistent with a canonical arginine finger. This observation contrasts with earlier models derived from yeast RanGAP and suggests that human RanGAP1 may follow a catalytic mechanism similar to classical small GTPase regulators like NF1. Together, these findings provide a framework of RanGAP1, linking autoinhibition, sumoylation, spatial organization at the NPC, and the catalytic mechanism. They also highlight how conformational regulation and post-translational modification coordinate efficient GTP hydrolysis in Ran during nuclear transport.
- Open Access
How Functional Variants Reconfigure the Rac2 Conformational Landscape
Rac2, a member of the Rho family of small GTPases, is a fundamental regulator of essential cellular processes. Pathogenic substitutions near and within the Switch II region, specifically D57N and E62K, have been implicated in oncogenesis and immunodeficiency. Despite their proximity, D57N is characterized as a loss-of-function mutation, while E62K is a constitutively active, gain-of-function mutation. In this study, we addressed several critical questions: (i) the structural basis of their altered cellular functions, (ii) how these variants rearrange the conformational ensemble, and (iii) the subsequent impact on cellular signaling networks. Using molecular dynamics (MD) simulations, we characterized the conformational dynamics of these Rac2 variants in GDP- and GTP-bound states. Our results demonstrate that Rac2 D57N predominantly adopts an inactive-like conformation, regardless of the bound nucleotide. GTP binding is insufficient to induce the canonical active state in this mutant. Conversely, Rac2 E62K maintains a nucleotide-dependent toggle, appearing inactive when bound to GDP and active when bound to GTP. Additionally, we examined the assembly of these variants with the regulator p50-RhoGAP. In the wild-type complex, GAP binding facilitates a shift toward a near-transition-state ensemble. In stark contrast, both the D57N and E62K complexes remain sequestered in a ground-ON state configuration, effectively trapping the GTPase and hindering GAP-mediated hydrolysis. While both Rac2 mutations result in immune system dysfunction, the underlying mechanisms are opposite: inactive vs. overactive. This work provides a high-resolution, mechanistic framework for understanding how localized perturbations in the switch loops landscape dictate systemic cellular outcomes.
Open AccessHow Functional Variants Reconfigure the Rac2 Conformational Landscape
Rac2, a member of the Rho family of small GTPases, is a fundamental regulator of essential cellular processes. Pathogenic substitutions near and within the Switch II region, specifically D57N and E62K, have been implicated in oncogenesis and immunodeficiency. Despite their proximity, D57N is characterized as a loss-of-function mutation, while E62K is a constitutively active, gain-of-function mutation. In this study, we addressed several critical questions: (i) the structural basis of their altered cellular functions, (ii) how these variants rearrange the conformational ensemble, and (iii) the subsequent impact on cellular signaling networks. Using molecular dynamics (MD) simulations, we characterized the conformational dynamics of these Rac2 variants in GDP- and GTP-bound states. Our results demonstrate that Rac2 D57N predominantly adopts an inactive-like conformation, regardless of the bound nucleotide. GTP binding is insufficient to induce the canonical active state in this mutant. Conversely, Rac2 E62K maintains a nucleotide-dependent toggle, appearing inactive when bound to GDP and active when bound to GTP. Additionally, we examined the assembly of these variants with the regulator p50-RhoGAP. In the wild-type complex, GAP binding facilitates a shift toward a near-transition-state ensemble. In stark contrast, both the D57N and E62K complexes remain sequestered in a ground-ON state configuration, effectively trapping the GTPase and hindering GAP-mediated hydrolysis. While both Rac2 mutations result in immune system dysfunction, the underlying mechanisms are opposite: inactive vs. overactive. This work provides a high-resolution, mechanistic framework for understanding how localized perturbations in the switch loops landscape dictate systemic cellular outcomes.